TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03655197
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
Study: NCT02544763
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT02544763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT01887197
Drug: inhaled hypertonic saline (7%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulized hypertonic saline (7%)
Study: NCT02658188
Drug: ASP8825
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01346917
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
Study: NCT03066518
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00619801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
Study: NCT03985514
Drug: Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
Study: NCT02742324
Drug: Ruxolotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
Study: NCT01320462
Drug: Smoking cessation counselling group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
Study: NCT02989025
Drug: 17 OHPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
Study: NCT01961180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02481141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02577575
Drug: Saline Nasal Spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT00913835
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
Study: NCT01754740
Drug: Uréia
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months.
Study: NCT01754740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
Study: NCT04083079
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
Study: NCT01685996
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02021409
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
Study: NCT01808612
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01808612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03038646
Drug: MIN-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00356642
Drug: GW842470X
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW842470X will be available as a yellow smooth water-in-oil cream.
Study: NCT00112385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
Study: NCT01003964
Drug: IP
Normalized name: GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
Study: NCT01003964
Drug: GP
Normalized name: GPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
Study: NCT04112368
Drug: Estradiol Transdermal Patch 0.1 mg/24 hrs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
Study: NCT04112368
Drug: Inactive Clear Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Study: NCT04112368
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study: NCT01166178
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg once a year via intravenous infusion
Study: NCT00356642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
Study: NCT01166178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to zoledronic acid once a year via intravenous infusion
Study: NCT01782664
Drug: 100 mg GSK2586184
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Study: NCT01782664
Drug: 200 mg GSK2586184
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Study: NCT01782664
Drug: 400 mg GSK2586184
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
Study: NCT01782664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to be taken twice daily with food for up to 84 days.
Study: NCT01082965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04037397
Drug: Anti Arrhythmics
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
Study: NCT01286012
Drug: Placebo: Conventional liquid bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
Study: NCT01286012
Drug: Erythrocyte Stimulating Agent (ESA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
Study: NCT06690450
Drug: Venofer® 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes
Study: NCT06690450
Drug: Venofer® 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
Study: NCT01286012
Drug: Intravenous (IV) Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
Study: NCT00196417
Drug: Standard heparin (UFH) versus certoparin (LMWH)
Normalized name: certoparin
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02174237
Drug: LNP1892
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of two strengths (5 and 25 mg)
Study: NCT02174237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02447406
Drug: AZD6094
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02051387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656695
Drug: Iminoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
Study: NCT03607110
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sedation drugs
Study: NCT02180672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One spray per nostril, per day.
Study: NCT01963832
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01963832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02837952
Drug: FDC IBU/APAP 250 mg/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC IBU/APAP 250 mg/500 mg
Study: NCT02837952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00003907
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Study: NCT01557569
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
Study: NCT01108705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0mg, once daily, until disease progression or toxicity
Study: NCT03376854
Drug: Neuromuscular Blocking Agents
Normalized name: NEUROMUSCULAR BLOCKING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
Study: NCT00077285
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03556007
Drug: LY3471851
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Study: NCT03556007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Study: NCT04099927
Drug: SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0410 monotherapy,given intravenously
Study: NCT00077285
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04469114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
Study: NCT03879655
Drug: VTS-270
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IT via LP infusion of VTS-270
Study: NCT00353119
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received placebo subcutaneously twice weekly
Study: NCT02642614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02642614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For blinding purposes
Study: NCT00254540
Drug: SU011248 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
Study: NCT02529514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 7 days at 10 pm every day
Study: NCT03439072
Drug: G-Pen
Normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Study: NCT03497702
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2 IV every 3 weeks for 4 cycles
Study: NCT03497702
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m2 IV every 3 weeks for 4 cycles
Study: NCT00934154
Drug: Melphalan+Prednisolone
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 2 mg, Prednisolone 16 mg
Study: NCT00229099
Drug: GerEPO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00266032
Drug: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
Study: NCT00266032
Drug: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
Study: NCT00266032
Drug: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
Study: NCT04019704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
Study: NCT01918358
Drug: Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01918358
Drug: Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01918358
Drug: Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01918358
Drug: Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01918358
Drug: Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01918358
Drug: Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00361855
Drug: NX-CP105
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01108133
Drug: 10 mg HydrocortisoneHöchst
Normalized name: HYDROCORTISONE 10 g in 100 g TOPICAL OINTMENT [HydrocortisoneLotion]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
Study: NCT01108133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00225160
Drug: acetyl L-carnitine
Normalized name: Nature's Way Acetyl L-Carnitine Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05318443
Drug: SIBP04
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
Study: NCT02951819
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
Study: NCT04634136
Drug: Full-spectrum Medical Canabis Product (HemPhar)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active substance
Study: NCT04634136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01648322
Drug: Neulasta® (pegfilgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose injection given once per chemotherapy cycle.
Study: NCT01879241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sugar pill manufactured to mimic Rasagiline 1 mg tablet
Study: NCT05781685
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
Study: NCT04652297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Placebo
Study: NCT01369576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75-7.5mg 14 doses 4 weeks
Study: NCT04652297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Placebo
Study: NCT04248153
Drug: BR55
Normalized name: Band-Aid Ourtone BR55 Bandages
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
Study: NCT02251041
Drug: Apotransferrin
Normalized name: melanotransferrin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02251041
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02251041
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01013259
Drug: Mutaflor
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
Study: NCT00456521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00009854
Drug: carmustine in ethanol
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00992082
Drug: ropivacaine, ketorolac and epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Study: NCT01013259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule matching the experimental treatment, according to the experimental arm
Study: NCT02074631
Drug: Calcium and vitamin D
Normalized name: Wellesse Calcium and Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
Study: NCT01116895
Drug: LEO 22811
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution
Study: NCT01116895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04024254
Drug: Folic Acid Tablet
Normalized name: Folic Acid Tablets
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 1 mg by mouth daily
Study: NCT02542280
Drug: ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
Study: NCT01426880
Drug: background treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).
Study: NCT02214628
Drug: Fovista® (anti-PDGF BB) plus anti-VEGF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01566565
Drug: Theophylline and Bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
Study: NCT01460615
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02011542
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a probiotic mixture
Study: NCT02011542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a pill with inactive ingredients.